GILD

Gilead Sciences, Inc. Press Releases

$113.94
*  
0.14
0.12%
Get GILD Alerts
*Delayed - data as of Jun. 2, 2015  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia
5/31/2015 9:00:00 AM - Business Wire
▲1.39 % Price Change since this news event. The Volume Ratio is 1.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
5/28/2015 8:30:00 AM - Business Wire
▲1.59 % Price Change since this news event. The Volume Ratio is 1.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
5/27/2015 5:00:00 PM - Business Wire
▲1.25 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Patent Challenges In Five Countries Dispute Validity Of Gilead's Claims To Hep C Drug Patents That Block Treatment For Up To 59 Million People
5/20/2015 9:00:00 AM - PR Newswire
▲3.47 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
5/18/2015 5:00:00 PM - Business Wire
▲2.69 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
5/12/2015 5:00:00 PM - Business Wire
▲7.93 % Price Change since this news event. The Volume Ratio is 1.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences Acquires EpiTherapeutics
5/6/2015 8:30:00 AM - Business Wire




Gilead Sciences Declares First Quarterly Cash Dividend
4/30/2015 4:02:00 PM - Business Wire


















Actavis Confirms Generic Letairis® Patent Challenge
4/3/2015 8:00:00 AM - PR Newswire